European policies in the management of tuberculosis among migrants

Lia D’Ambrosio a,b, Rosella Centis a, Masoud Dara c, Ivan Solovic d, Giorgia Sulis e, Alimuddin Zumla f, Giovanni Battista Migliori a,b

a World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Institute, IRCCS, Via Roncaccio 16, 21049, Tradate, Italy
b Public Health Consulting Group, Lugano, Switzerland
c World Health Organization Regional Office for Europe, UN City, Copenhagen, Denmark
d National Institute for TB, Lung Diseases and Thoracic Surgery, Catholic University Ruzomberok, Vysoké Tatry, Slovakia
e Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV and TB Elimination, University of Brescia, Brescia, Italy
f Center for Clinical Microbiology, Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK

SUMMARY

Globally 10.4 million new tuberculosis (TB) incident cases were estimated to have occurred in 2015, of which 3% were reported in the World Health Organization European Region. Importantly, about 25% of the global multidrug-resistant TB (MDR-TB) cases are reported in the European Region, representing one of the greatest challenges to TB control; these are reported particularly in the countries of the Former Soviet Union. Over a quarter of TB cases in the European Union and European Economic Area (EU/EEA) are reported among foreign-born individuals. In line with the recent increase of migration flows towards Europe, TB among migrant populations is also on the rise, emphasizing the need for a better understanding of the TB trends at the regional and sub-regional levels, and of the existing policies on migrants and refugees. The present article is aimed at describing the policies and practices of European countries with a low and intermediate TB incidence with regard to the detection and management of TB among migrant populations is also on the rise, emphasizing the need for a better understanding of the TB trends at the regional and sub-regional levels, and of the existing policies on migrants and refugees. The present article is aimed at describing the policies and practices of European countries with a low and intermediate TB incidence with regard to the detection and management of TB among migrants and refugees. The present article is aimed at describing the policies and practices of European countries with a low and intermediate TB incidence with regard to the detection and management of TB among migrants and refugees. The present article is aimed at describing the policies and practices of European countries with a low and intermediate TB incidence with regard to the detection and management of TB among migrants and refugees.
protection from deportation until the end of treatment) has to be ensured to undocumented migrants as well, as recommended by the WHO.12–16

2. TB and refugees

Over one million refugees and migrants entered Europe in 2015, while this was ‘only’ 216 000 in 2014.5,17 Between January 1 and September 30, 2016 an estimated 302 335 new migrants reached the Europe Region, with 3498 deaths/missing officially reported. Interestingly, over 60% of those landing in Europe after crossing the Mediterranean Sea were born in 10 countries, as summarized in Figure 1.17 As of today, the top four countries of origin for asylum seekers are the Syrian Arab Republic (28% of total arrivals), Afghanistan (14%), Iraq (9%), and Nigeria (8%).17

The aim of the present article is to describe the policies and practices of European countries with a low and intermediate TB incidence with regard to the detection and management of TB and LTBI among refugees in Europe.6,18

3. The European survey on policies

The survey was performed between October 2015 and February 2016, and was coordinated by the TB Advocacy ad-hoc Working Group of the European Respiratory Society (ERS), in collaboration with the WHO Regional Office for Europe and the European Region of the International Union Against Tuberculosis and Lung Disease (The Union).19 The survey included multiple choice and open-ended questions concerning screening and management of TB and LTBI among refugees in Europe. It was completed by the coordinators of national TB programmes of all EU/EEA countries of the WHO European Region, plus six additional EU candidate countries (Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, and Turkey) and Switzerland.19

4. Results

All countries except two (36/38, 94.7%) answered the questionnaire. A summary of the core results is presented in Table 1. Thirty-one countries (86.1%) reported that screening is performed for active TB and 19 for LTBI. Eight countries only (22.2%) collected data on LTBI treatment outcomes. Interestingly, about half of the countries not yet screening are developing TB and LTBI screening plans. National guidelines in force imply a legal obligation to screen for TB and/or LTBI in almost 60% of the surveyed countries (21/36).

Country representatives reported details on how screening practices are organized. Active TB screening is essentially based on diagnostic algorithms including different combinations of symptom-based questionnaires, bacteriological examinations, and chest radiography. LTBI screening is conducted through different combinations of interferon-gamma release assays (IGRAs) and/or the tuberculin skin test (TST).

Confirming previous findings,11 LTBI screening was found to be performed by TST only in 22.2% of the countries (8/36), by TST plus IGRA in 30.5% of the countries, and by TST plus IGRA only in selected cases in 11% of the countries. Screening practices were found to be organized differently based on the setting- or country-specific organization of health services. In the majority of countries

![Figure 1. Recent evidence on migrant movements to Europe (available at http://data.unhcr.org/mediterranean/regional.php, last accessed September 30, 2016).](http://data.unhcr.org/mediterranean/regional.php)
(n = 22, 61.1%), both TB and LTBI screening are done in devoted refugee centres. In 22 countries (61.1%), screening interventions are managed through a strict collaboration between governmental and private sector staff.

The majority of countries (75%) answered that screening practices are consistent with both national and international guidelines in force. The proportion decreased to 52.7% (n = 19) for LTBI screening. Several countries reported that infection control measures were considered suboptimal, although respirators were reported to be available to protect health staff to complement administrative measures.

5. From evidence to recommendations

The results of the study are pivotal to coordinate future initiatives in favour of an improved management of refugees in Europe.19 The high response rate confirmed that the topic is of importance to the agenda of the different countries. The relevant
Table 2

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Ensure adequate prevention, diagnosis, and treatment of TB and LTBI based on the End TB Strategy</td>
<td>LTBI management is a core intervention to pursue TB elimination; diagnosis and treatment of LTBI might be not feasible in all countries. Solid evidence is needed to guide public health interventions; operational research is necessary to guide rational introduction of the diagnostics and drugs. Evidence on yield and the cost-effectiveness of screening practices is needed.</td>
</tr>
<tr>
<td>2. Provide quality surveillance, monitoring, and evaluation, coupled with operational research</td>
<td>The recommendation aims at encouraging unrestricted access to TB services. Universal access includes adequate management of comorbidities.</td>
</tr>
<tr>
<td>3. Ensure timely screening for TB among refugees born in middle and high TB incidence countries</td>
<td>The package includes protective measures for staff, as well as HIV testing and counselling to detect HIV and TB–HIV co-infected individuals.</td>
</tr>
<tr>
<td>4. Prevent stigmatization and stereotypes, of both TB infected people and vulnerable groups</td>
<td></td>
</tr>
<tr>
<td>5. Promote universal access to LTBI (in the countries where these are offered) and TB services (prevention, diagnosis, and treatment)</td>
<td></td>
</tr>
<tr>
<td>6. Ensure quality infection control in settings where refugees are hosted, screened, and treated</td>
<td></td>
</tr>
</tbody>
</table>

TB, tuberculosis; LTBI, latent tuberculosis infection.

* From Dara et al.,27 modified.

inter-country variability in policies reflects the difficulty, at the European level, of coordinating complex interventions, which imply technical expertise, organization of different services, and important funding, as well as delicate legal and ethical issues. As expected, more information was available on TB than on LTBI screening practices. Feasibility issues are clearly driving these results. In some countries, the large numbers of arrivals and the increased mobility make LTBI screening even more difficult to perform. Further research, providing data on the yield of different screening practices and on their cost-effectiveness, will provide better information to design rational and sustainable screening plans.

A core research priority, given the increased breakdown risk (LTBI progressing to TB disease because of the prevalent unhealthy travel conditions), is represented by the management of LTBI.1,10,11 This intervention is, in fact, crucial if the TB elimination strategy is taken into consideration.1,10,11 From the organizational point of view, inter-sectoral collaboration involving governmental and private services is key to increase the cultural sensitivity of TB services. The importance of ensuring quality infection control measures whenever TB patients are hosted needs also to be underlined.20 The results of this and similar studies will support the proper implementation of the End TB Strategy, the TB Action Plan for the WHO European Region 2016–2020,21 and the Health 2020 Policy Framework22 to address inequity. The final goal of these strategies is to end TB and ultimately eliminate TB.10,11,23–25 Additional evidence is obviously necessary.26

The ERS and the WHO Regional Office for Europe have proactively launched a new branch of the TB Consilium (an internet-based and cost-free platform supporting clinicians managing difficult-to-treat TB cases) to allow better cross-border TB control among refugees and migrants. The new function is presently live and accessible at the TB Consilium website (http://www.tbconsilium.org). The hope is to contribute to improve prevention, diagnostic, and treatment services for migrants and refugees. Furthermore, the same ERS TB Advocacy ad-hoc Committee, in collaboration with the WHO Office for Europe and The Union Europe Region have developed recommendations for the better management of migrants and refugees28 (Table 2).

In conclusion, the new interest raised among politicians and policymakers on these delicate issues needs to be channelled into concrete actions promoting unrestricted access of migrants and refugees to TB prevention, diagnostic, and treatment services, while ensuring that individual human rights are met and that the community is protected from further transmission of Mycobacterium tuberculosis.

Financial support: No funding was received by the authors.

Conflict of interest: No competing interest declared.

References


